Biopharma company CSL has received US regulatory approval for a formulation of its Flucelvax Quadrivalent influenza vaccine.
The formulation is a four-strain, cell culture-derived vaccine, which can also be used for children aged four years and older. It is one of the two formulations of Flucelvax for which phase 3 clinical trials had been under way.
CSL acquired pharma giant Novartis' flu vaccine business in 2015 for $US275 million ($A380.65 million) in a deal that included the North Carolina vaccine plant, where Flucelvax will be manufactured.
CSL plans to market the vaccine during the 2016-2017 US flu season.
Share
